The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Capecitabine/ Temozolomide Elicits 'Extraordinary' Responses in Chemo-Resistant NETs

Published Online: 4:27 PM, Wed January 15, 2014
Robert Lance Fine, MD

Robert Lance Fine, MD

Patients with carcinoid and pituitary NETs, who have been traditionally chemo-resistant, may obtain "extraordinary responses" with capecitabine and temozolomide (CAPTEM), according to data from an interim analysis of an ongoing phase II study. Robert Lance Fine, MD, reported these data at a presscast prior to the 2014 Gastrointestinal Cancers Symposium.

In the pituitary group, “There were two of the three patients who were end-stage disease on respirators because of spinal-cord compression from their tumor. They both had complete responses, got off-machine, and now are still free of tumor, close to 4 years out now and on continual treatment,” said Fine, lead study author and an associate professor of Medicine at New York Presbyterian Hospital-Columbia University Medical Center.

CAPTEM demonstrated tumor sh­­rinkage in 43% of patients in the study, all with progressive, moderately, and well-differentiated metastatic NETs (N=28), and the combination therapy stalled tumor growth in 54% of these patients. CAPTEM either stalled disease progression or shrank tumors in 95% of patients whose disease worsened after standard high-dose octreotide, according to the ASCO written statement. Median progression-free survival (mPFS) was 30 months.

Notably, 41% of patients with carcinoid tumors (n=12) experienced tumor shrinkage. Response rate (RR) to chemotherapy for these patients is generally 0-4%, according to Fine.
Among the four patients with pituitary tumors resistant to radiation therapy, chemotherapy, and surgery, two had complete remissions (CR) with CAPTEM, one had a 75% reduction in tumor size, and one has had stable disease (SD) for 5 years.

The primary objective of the study is RR based upon RECIST, and secondary objectives include PFS, overall survival (OS; from time of initiation of therapy), and toxicity evaluation. Inclusion criteria were: age <80; ECOG performance status (PS) 0-2; adequate hematologic, renal, and liver function; and failure on high-dose octreotide.

Various subtypes of metastatic NETs were treated as part of the study (See Table).

Table. CAPTEM Interim Study Results

  # of Subjects % SD % PR % CR % PD PFS OS
Carcinoid
(typical and atypical)
12 58 33 8 0 >23.9 >31.5
Pituitary 3 0 33 67 0 >41.6 >41.6
Pancreatic NET 11 55 36 0 9 >20.0 >24.4
Medullary Thyroid 2 100 0 0 0 >22.8 >27.7
Overall 28 54 32 11 3 >22.2 >29.1

PD=progressive disease; PR=partial response

Most patients experienced only mild side effects. “The rate of serious side effects was low with CAPTEM. We had no hospitalizations or treatment-related deaths,” Fine said. The most common Grade 3/4 toxicities were lymphopenia (35%), hyperglycemia (6%), thrombocytopenia (3%), and diarrhea (3%).

Fine and the study’s co-authors believe that CAPTEM may eventually replace all other second-line therapies for advanced neuroendocrine tumors, ASCO said in a written statement.

Fine and colleagues are working on other CAPTEM studies that they hope will make the therapy even more effective (eg, combining CAPTEM with drugs that block the platelet-derived growth factor [PDGF] pathway).

“In this study we’re seeing patients who had been given 6 months to live that are still alive 8 years after starting CAPTEM,” Fine said. “The regimen was effective even in patients with tumors that hadn’t responded to any other standard treatment, including chemotherapy, high-dose octreotide, small molecule inhibitors, radiation or surgery.”


Fine RL, Gulati AP, Tsushima D, et al. Prospective phase II study of capecitabine and temozolomide (CAPTEM) for progressive, moderately, and well-differentiated metastatic neuroendocrine tumors. Presented at: 2014 Gastrointestinal Cancers Symposium (Presscast); January 14, 2014. Abstract 179.

<<< Back to the GI 2014 conference page



Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.